Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Mingozzi

Showing results (11-20 of 138) with videos related to

Pageof 14
Sort By:
Discovery Medicine|July 4, 2013
Humoral immunity to AAV vectors in gene therapy: challenges and potential solutionsElisa Masat, Giulia Pavani, Federico Mingozzi
Human Gene Therapy|August 25, 2017
Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After TrialCéline Vandamme, Oumeya Adjali, Federico Mingozzi
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 24, 2020
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene TransferHelena Costa Verdera, Klaudia Kuranda, Federico Mingozzi
Frontiers in Immunology|May 5, 2020
Human Immune Responses to Adeno-Associated Virus (AAV) VectorsGiuseppe Ronzitti, David-Alexandre Gross, Federico Mingozzi
Journal of Pediatric Gastroenterology and Nutrition|January 17, 2015
Adeno-associated virus vector-based gene therapy for monogenetic metabolic diseases of the liverNorman Junge, Federico Mingozzi, Michael Ott, et al.
Annals of Translational Medicine|August 9, 2019
Progress and challenges of gene therapy for Pompe diseaseGiuseppe Ronzitti, Fanny Collaud, Pascal Laforet, et al.
Clinical & Developmental Immunology|January 24, 2014
Tregitope peptides: the active pharmaceutical ingredient of IVIG?Anne S De Groot, Leslie Cousens, Federico Mingozzi, et al.
Human Gene Therapy|January 22, 2024
Complement System Response to Adeno-Associated Virus Vector Gene TherapyElizabeth Kropf, David M Markusic, Anna Majowicz, et al.
Thrombosis and Haemostasis|March 1, 2005
The factor VIII D1241E polymorphism is associated with decreased factor VIII activity and not with activated protein C resistance levelsDaniela Scanavini, Cristina Legnani, Barbara Lunghi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 7, 2022
Gene therapy access: Global challenges, opportunities, and views from Brazil, South Africa, and IndiaKenneth Cornetta, Martín Bonamino, Johnny Mahlangu, et al.
Pageof 14

Showing results (11-20 of 138) with videos related to

Sort By:
Pageof 14
Discovery Medicine|July 4, 2013
Humoral immunity to AAV vectors in gene therapy: challenges and potential solutionsElisa Masat, Giulia Pavani, Federico Mingozzi
Human Gene Therapy|August 25, 2017
Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After TrialCéline Vandamme, Oumeya Adjali, Federico Mingozzi
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 24, 2020
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene TransferHelena Costa Verdera, Klaudia Kuranda, Federico Mingozzi
Frontiers in Immunology|May 5, 2020
Human Immune Responses to Adeno-Associated Virus (AAV) VectorsGiuseppe Ronzitti, David-Alexandre Gross, Federico Mingozzi
Journal of Pediatric Gastroenterology and Nutrition|January 17, 2015
Adeno-associated virus vector-based gene therapy for monogenetic metabolic diseases of the liverNorman Junge, Federico Mingozzi, Michael Ott, et al.
Annals of Translational Medicine|August 9, 2019
Progress and challenges of gene therapy for Pompe diseaseGiuseppe Ronzitti, Fanny Collaud, Pascal Laforet, et al.
Clinical & Developmental Immunology|January 24, 2014
Tregitope peptides: the active pharmaceutical ingredient of IVIG?Anne S De Groot, Leslie Cousens, Federico Mingozzi, et al.
Human Gene Therapy|January 22, 2024
Complement System Response to Adeno-Associated Virus Vector Gene TherapyElizabeth Kropf, David M Markusic, Anna Majowicz, et al.
Thrombosis and Haemostasis|March 1, 2005
The factor VIII D1241E polymorphism is associated with decreased factor VIII activity and not with activated protein C resistance levelsDaniela Scanavini, Cristina Legnani, Barbara Lunghi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 7, 2022
Gene therapy access: Global challenges, opportunities, and views from Brazil, South Africa, and IndiaKenneth Cornetta, Martín Bonamino, Johnny Mahlangu, et al.
Pageof 14